Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Kamada Ltd. Regulatory Filings 2015

Jun 22, 2015

6874_rns_2015-06-22_2ed0adcc-34b6-4f7c-a56b-9f0bcc1620b2.htm

Regulatory Filings

Open in viewer

Opens in your device viewer

_________ false

C002����� ��"�2PublicKAMADA LTD9024Corporation no: 511524605Stock Exchange/Market: -11934380Sapir 7 P.O.B 4081 , Ness-Ziona 74036 , ISRAEL ,Tel: 08-9406472 , Fax: 08-9406473E.mail address: [email protected] via MAGNA: 22/06/2015              Time of broadcast: 13:30 13:28:16

Company site: www.kamada.com

Reference: 2015-02-053577

Israel Securities Authority Tel Aviv Stock Exchange
www.isa.gov.il www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
nsplant_rejection_FINAL_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 03/06/2015
- - -
Name of the Signatory: : Cohen Liat , Position of Signatory in the reporting corporation: Company Controller , Name of Employer Company: .
Sapir Telephone: 08-9913168 , Facsimile: 08-9912183 , E-mail: [email protected] 1